Along these lines, MYC downregulation is needed for the effect of ERK1/2i in other mut KRAS tumors such as pancreatic cancer56, supporting a role for MYC in maintaining tumor integrity in the context of targeted therapies to the RAS pathway. Here, KRAS is linked to neoplasm.